TICKERNERD
Menu
ORICORICHealthcare · Biotechnology

ORIC Stock Forecast: Oric Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$14
+2.31% on the day

The 14 Wall Street analysts covering Oric Pharmaceuticals, Inc. hold a median 12-month price target of $22 — +51.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$1.5B
Ticker Nerd rank
50 / 100
Median analyst target
$22
Analysts covering
14
Total return, dividends reinvested
1W
+2.4%
1M
+31.1%
YTD
+73.6%
1Y
+46.5%
From 52W high
−3.1%
From 52W low
+90.0%
$7
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ORIC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Oric Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
50 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
79
Volatility
75
Momentum
67
Quality
66
Growth
58
Accruals
42
Size
40
Revisions
32
Issuance
29

Value (79): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (29): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ORIC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ORIC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26ORICHigh $27Median $22Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says14 analysts
13 Buy1 Hold0 Sell
Low $14Median $22High $27

The green dot is the last close — the median target sits +51.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 Aug 2026HC Wainwright & Co.MaintainsBuy$25 → $27
8 June 2026HC Wainwright & Co.ReiteratesBuy—
8 June 2026HC Wainwright & Co.ReiteratesBuy$25
15 May 2026Goldman SachsUpgradeBuy—
5 May 2026CitigroupMaintainsBuy—
2 Apr 2026HC Wainwright & Co.ReiteratesBuy—
1 Apr 2026WedbushMaintainsOutperform—
13 Mar 2026HC Wainwright & Co.ReiteratesBuy—
24 Feb 2026CitigroupMaintainsBuy—
24 Feb 2026HC Wainwright & Co.MaintainsBuy—
24 Feb 2026WedbushReiteratesOutperform—
13 Jan 2026WedbushReiteratesOutperform—
7 Jan 2026Piper SandlerInitiatesOverweight—
8 Dec 2025WedbushReiteratesOutperform—
8 Dec 2025Wells FargoMaintainsOverweight—
20 Nov 2025Evercore ISI GroupInitiatesOutperform—
18 Nov 2025JP MorganMaintainsOverweight—
18 Nov 2025Wolfe ResearchInitiatesPeer Perform—
17 Nov 2025CitigroupMaintainsBuy—
14 Nov 2025HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ORIC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ORIC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
6
Fundamentals

Oric Pharmaceuticals, Inc. (ORIC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−9.7×

Cheaper than 93% of US stocks

Price / sales
—
Price / book
3.9×

Cheaper than 28% of US stocks

EV / EBITDA
−7.8×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−39.8%

Higher than 24% of US stocks

Return on assets
−26.0%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ORIC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ORICOric Pharmaceuticals, Inc.$1.5B
50
NVAXNovavax, Inc.$1.5B
54
SLBTSL Science Holding Ltd.$1.5B
0
AVBPArrivent BioPharma, Inc.$1.4B
35
INBXInhibrx Biosciences, Inc.$1.5B
26
LTGOLatigo Biotherapeutics, Inc.$1.4B
0
LBRXLB Pharmaceuticals, Inc.$1.5B
6

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Oric Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ORIC news & analysis

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 7 Aug 2026neutral

ORIC Pharmaceuticals announced that on August 3, 2026, it granted 125,400 non-qualified stock options and 20,550 restricted stock units to five new non-executive employees who joined the company in July 2026. The grants were made under Nasdaq Listing Rule 5635(c)(4) as inducement awards.

Why it matters — This disclosure reflects ORIC's equity-based incentive awards to newly hired personnel, which is relevant to investors tracking the company's compensation and share-dilution practices.

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates

GlobeNewsWire · 3 Aug 2026positive

ORIC Pharmaceuticals reported second quarter 2026 financial results and operational updates, including initiation of the Himalayas-1 global Phase 3 trial in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone, and a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for that trial. The company expects to provide a rinzimetostat program update and enozertinib clinical updates in the second half of 2026 ahead of a potential registrational trial, and its roughly $388 million in cash and investments is expected to fund operations into the second half of 2028.

Why it matters — ORIC watchers would care because the quarter brought a new global Phase 3 trial and a Bayer collaboration, along with near-term program updates that could shape the company's registrational path.

FAQ

Frequently asked questions about ORIC stock

What is the ORIC stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Oric Pharmaceuticals, Inc. have a median 12-month price target of $22, with estimates ranging from $14 to $27. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ORIC stock a buy right now?

Of the 14 analysts covering Oric Pharmaceuticals, Inc., 13 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Oric Pharmaceuticals, Inc. 50 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ORIC?

As at 22 Aug 2026, Oric Pharmaceuticals, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (79 of 100).

Will ORIC stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +51.4% from the last close, and Ticker Nerd's factor model ranks Oric Pharmaceuticals, Inc. 50 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ORIC stock forecast for 2030?

No analyst covering Oric Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ORIC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $27 over the next 12 months.

How has ORIC stock performed over the past year?

Oric Pharmaceuticals, Inc. returned +46.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Oric Pharmaceuticals, Inc. do?

Oric Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that address mechanisms of therapeutic resistance in cancer.

What is the latest news on ORIC?

The most recent item we track (GlobeNewsWire, 7 Aug 2026): "ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)". ORIC Pharmaceuticals announced that on August 3, 2026, it granted 125,400 non-qualified stock options and 20,550 restricted stock units to five new non-executive employees who joined the company in July 2026. The grants were made under Nasdaq Listing Rule 5635(c)(4) as inducement awards.

Company

About Oric Pharmaceuticals, Inc.

Oric Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that address mechanisms of therapeutic resistance in cancer. The company targets innate, acquired, and bypass resistance to overcome limitations in existing cancer treatments, with a particular emphasis on hormone-dependent cancers, key tumor dependencies, and precision oncology. Its lead clinical-stage product candidates include rinzimetostat (ORIC-944), an allosteric inhibitor of the polycomb repressive complex 2 under investigation in Phase 1b studies for metastatic castration-resistant prostate cancer, often in combination with androgen receptor inhibitors, and enozertinib (ORIC-114), a brain-penetrant, orally bioavailable irreversible inhibitor targeting EGFR exon 20 insertion mutations, atypical EGFR mutations including PACC, and HER2 exon 20 mutations in non-small cell lung cancer patients, demonstrating systemic and central nervous system activity. Oric Pharmaceuticals Inc. maintains ongoing Phase 1b trials for these candidates, either as monotherapy or in combinations, and holds clinical development collaborations with partners such as Pfizer, Bayer, and Johnson & Johnson. Founded in 2014 and headquartered in South San Francisco, California, the company plays a significant role in advancing oncology innovations against resistance challenges.

CEO Dr. Jacob M. Chacko M.B.A., M.D. · 111 employees · United States · https://www.oricpharma.com